Español 
English
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Artículos Relacionados
-
UDIBI
Characterization of a Complex Mixture of Immunomodulator Peptides Obtained from Autologous Urine. VER MÁS
-
UDIBI
Fecha de publicación: 20 de marzo del 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear...
-
-
-
UDIBI
Fecha de publicación: Septiembre 2019 A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced...
-
UDIBI
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...
-
UDIBI
Fecha de publicación: 20 Septiembre 2019 Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable...
-
UDIBI
Fecha de publicación: 8 noviembre 22 Altered neutrophil-to-lymphocyte ratio in sepsis secondary to canine parvoviral enteritis treated with and...
